Anatolian Current Medical Journal

Anatolian Current Medical Journal

Evaluation of the serum visfatin eotaxin and fetuin-A levels of patients with type 2 diabetes mellitus

Yazarlar: Hacer KAYHAN KAYA, Abdurrahman ŞERMET, Zafer PEKKOLAY, Ezel TAŞDEMİR, Dilek AYGÜN KEŞİM

Cilt 4 , Sayı 1 , 2022 , Sayfalar 113 - 119

Konular:Sağlık Bilimleri ve Hizmetleri

Anahtar Kelimeler:Visfatin,Eotaxin,Fetuin-A,Type 2 diabetes mellitus

Özet: Objective: The aim of this study was to determine the serum visfatin, eotaxin and fetuin-A levels in patients with normal BMI and overweight type 2 diabetes mellitus (T2DM). Material and Method: This study perform in 30 T2DM patients and in 20 healthy subjects. Test subjects were divided into four groups as two diabetics and two controls. Diabetics with a body mass index (BMI) of 26.2-29.9 kg/m2 were included in the overweight diabetic group (OD), and those with a body mass index of 20.9-24.9 kg/m2 were included in the normal BMI diabetic group (ND). The volunteers in the control group were also divided into two groups as overweight (OC) and normal BMI (NC). Smoking and alcohol users were not included in the study. In addition, patients with significant diabetic complications such as retinopathy, hypertension, neuropathy, renal failure, and cardiovascular disease were excluded from the study. The serum visfatin eotaxin and fetuin-A levels were measured using the ELISA method. The Mann-Whitney U test was used to compare the data of the groups, while Spearman’s analysis was applied for the correlations. Results: The visfatin levels of the OD and ND were significantly higher compared to those of their control groups (p<0.05 and p<0.05 respectively). In addition, the eotaxin levels of the diabetic patients both OD and ND were significantly higher than those of their control group (p<0.001 and p<0.05, respectively). Serum fetuin-A level was not different between groups. Conclusion: Serum visfatin and eotaxin levels are high in patients with T2DM, and this elevation is dependent on BMI. In addition, visfatin level is high in overweight non-diabetic subjects.


ATIFLAR
Atıf Yapan Eserler
Henüz Atıf Yapılmamıştır

KAYNAK GÖSTER
BibTex
KOPYALA
@article{2022, title={Evaluation of the serum visfatin eotaxin and fetuin-A levels of patients with type 2 diabetes mellitus}, volume={4}, number={113–119}, publisher={Anatolian Current Medical Journal}, author={Hacer KAYHAN KAYA,Abdurrahman ŞERMET,Zafer PEKKOLAY,Ezel TAŞDEMİR,Dilek AYGÜN KEŞİM}, year={2022} }
APA
KOPYALA
Hacer KAYHAN KAYA,Abdurrahman ŞERMET,Zafer PEKKOLAY,Ezel TAŞDEMİR,Dilek AYGÜN KEŞİM. (2022). Evaluation of the serum visfatin eotaxin and fetuin-A levels of patients with type 2 diabetes mellitus (Vol. 4). Vol. 4. Anatolian Current Medical Journal.
MLA
KOPYALA
Hacer KAYHAN KAYA,Abdurrahman ŞERMET,Zafer PEKKOLAY,Ezel TAŞDEMİR,Dilek AYGÜN KEŞİM. Evaluation of the Serum Visfatin Eotaxin and Fetuin-A Levels of Patients with Type 2 Diabetes Mellitus. no. 113–119, Anatolian Current Medical Journal, 2022.